SCHEMBL6456622

SCHEMBL6456622

CN(C)c1ccnc(NC2CCC(NC(=O)Cc3cccc4ccccc34)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.48
MCHR1 Q99705 5/20 0.43
CDK5 Q00535 3/20 0.42
CDK5R1 Q15078 3/20 0.42
POLB P06746 1/20 0.41
GSK3B P49841 1/20 0.41
ALDH1A1 P00352 3/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
ADRA2A P08913 1/20 0.40
ACHE P22303 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6456613 1.00 SIGMAR1 (0.48) SIGMAR1MCHR1CDK5CDK5R1POLB
SCHEMBL6456719 0.90 MCHR1 (0.42) SIGMAR1MCHR1OPRM1OPRD1ADRA2A
SCHEMBL6456731 0.90 MCHR1 (0.42) SIGMAR1MCHR1OPRM1OPRD1ADRA2A
SCHEMBL6874855 0.87 ALDH1A1 (0.41) SIGMAR1MCHR1CDK5GSK3BALDH1A1
SCHEMBL6868904 0.87 SIGMAR1 (0.46) SIGMAR1MCHR1ALDH1A1L3MBTL1CDK2
SCHEMBL6874860 0.87 ALDH1A1 (0.41) SIGMAR1MCHR1CDK5GSK3BALDH1A1
SCHEMBL6868909 0.87 SIGMAR1 (0.46) SIGMAR1MCHR1ALDH1A1L3MBTL1CDK2
SCHEMBL6831906 0.86 MTNR1A (0.47) MCHR1CDK5GSK3BCDK2ADRA2A
SCHEMBL6831908 0.86 MTNR1A (0.47) MCHR1CDK5GSK3BCDK2ADRA2A
SCHEMBL6867944 0.85 ADRA2A (0.42) MCHR1ALDH1A1ADRA2AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 SIGMAR1 283/4885MCHR1 2/4885CDK5 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.